Diffuse infiltrative lung diseases

Diffuse infiltrative lung diseases (DILD) comprise a heterogeneous group of disorders characterized by widespread involvement of the alveolar–interstitial compartment, leading to impaired gas exchange, restrictive ventilatory impairment, and progressive respiratory disability.

Definition and Epidemiology

Chronic diffuse infiltrative lung disease refers to conditions that predominantly affect the alveoli and lung interstitium, with secondary involvement of the airways and pulmonary vasculature. These disorders collectively affect roughly 70 per 100,000 population, with post‑inflammatory pulmonary fibrosis and idiopathic pulmonary fibrosis (IPF) being among the most frequent diagnoses.

Other major entities within the DILD spectrum include sarcoidosis, interstitial lung disease associated with collagen vascular disorders, hypersensitivity pneumonitis, pneumoconioses (asbestosis, silicosis, coal worker’s pneumoconiosis, berylliosis), drug‑ and radiation‑induced lung disease, and malignant diffuse infiltrative lung disease such as lymphangitic carcinomatosis. A combination of environmental exposure and genetic susceptibility is thought to modulate individual risk across these conditions.

Pathogenesis and Common Injury Pathway

Despite diverse etiologies, most DILD entities converge on a shared pathogenetic cascade involving initial tissue injury, sustained inflammation, and variable progression to remodeling and fibrosis. Experimental models using bleomycin, paraquat, radiation, and cyclophosphamide demonstrate injury patterns similar to human idiopathic interstitial pneumonias, with early damage to type I alveolar epithelial cells and capillary endothelial cells, followed by edema, neutrophilic influx, and subsequent recruitment of lymphocytes and macrophages.

Under growth factor stimulation, type II epithelial cells proliferate and spread to replace damaged type I cells, while deposition of collagen, elastin, and other extracellular matrix components in the interstitium leads to irreversible architectural distortion and fibrosis. Variations in the magnitude and localization of inflammation, granuloma formation, vascular injury, and fibroblast activation help define specific clinicopathologic entities such as usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP), hypersensitivity pneumonitis, or sarcoidosis.

Clinical Presentation and History

Dyspnea of insidious onset, initially manifesting with extreme exertion, and a persistent non‑productive cough are the cardinal symptoms of chronic DILD. Chest pain and hemoptysis are atypical and suggest alternative or overlapping pathology such as vasculitis, pulmonary embolism, or diffuse alveolar hemorrhage. Symptom duration is diagnostically important: months to years of stable or slowly progressive dyspnea strongly favor non‑infectious interstitial disease, whereas evolution over days to weeks raises concern for infection, acute interstitial pneumonia, or drug‑induced acute lung injury.

A meticulous history must address:

• Fever and systemic symptoms, which may occur in non‑infectious DILD (e.g. sarcoidosis, hypersensitivity pneumonitis, collagen vascular disease, drug‑induced disease) but always warrant exclusion of infection, particularly mycobacterial, fungal, or Pneumocystis jirovecii pneumonia in immunocompromised hosts.
• Occupational and environmental exposures, including inorganic dusts (asbestos, silica) and organic antigens (moldy hay, grain, bird proteins, contaminated humidifiers), which are classic precipitants of pneumoconioses and hypersensitivity pneumonitis.
• Drug exposures—prescription, over‑the‑counter, chemotherapeutic, antiarrhythmic, anti‑inflammatory, and illicit substances—because drug‑induced parenchymal lung disease accounts for an estimated several hundred thousand cases annually and roughly 3% of infiltrative lung disease overall.
• Symptoms suggestive of collagen vascular disease or vasculitis (Raynaud phenomenon, photosensitivity, rashes, arthritis) because pulmonary involvement often represents a manifestation of systemic autoimmunity.

Physical Examination and Laboratory Evaluation

Physical examination, although less specific than history, can reveal extrapulmonary clues: synovitis, telangiectasia, sclerodactyly, malar rash suggest collagen vascular disease, whereas uveitis, erythema nodosum, or plaquelike cutaneous lesions point toward sarcoidosis. Signs of underlying malignancy (breast or abdominal masses, hepatomegaly, occult gastrointestinal bleeding) may accompany lymphangitic carcinomatosis. Cardiovascular examination is essential to distinguish chronic pulmonary venous congestion from primary interstitial pathology.

Laboratory studies include:

• Complete blood count and biochemistry to detect cytopenias, hypercalcemia, elevated liver enzymes, or eosinophilia, which can suggest sarcoidosis, collagen vascular disease, malignancy, chronic eosinophilic pneumonia, or eosinophilic granuloma.
• Autoimmune serology (antinuclear antibodies, rheumatoid factor) to support collagen vascular disease, with recognition that low‑titer positivity is common in IPF and thus not specific.
• Serum angiotensin‑converting enzyme (ACE) level, often elevated in sarcoidosis but also in miliary tuberculosis, berylliosis, asbestosis, and silicosis.
• Antigen‑specific antibodies for hypersensitivity pneumonitis, which confirm significant exposure but are not themselves diagnostic; disappearance of antibody following antigen avoidance aligns more strongly with causality.

Imaging: Chest Radiography and High‑Resolution CT

Chest radiographs in DILD often show bilateral, relatively symmetric interstitial, alveolar, or mixed alveolar–interstitial patterns, though up to some patients may have normal films despite marked clinical and functional impairment. Ancillary radiographic signs can narrow the differential, for example:

• Hilar adenopathy suggesting sarcoidosis, lymphoma, carcinoma, or granulomatous infection.
• Pleural effusion associated with collagen vascular disease, asbestosis, lymphangiomyomatosis, or tuberculosis.
• Pneumothorax pointing toward eosinophilic granuloma, Pneumocystis pneumonia, or lymphangiomyomatosis.
• Upper‑zone predominance implicating silicosis, eosinophilic granuloma, or sarcoidosis.
• Peripheral infiltrates suggesting chronic eosinophilic pneumonia, bronchiolitis obliterans organizing pneumonia (BOOP), or certain drug‑induced injuries.

High‑resolution computed tomography (HRCT) has transformed DILD evaluation, enabling precise characterization of the distribution, pattern, and extent of parenchymal involvement and frequently yielding a confident diagnosis in 60–80% of cases when integrated with clinical and radiographic data. HRCT can detect subtle interstitial abnormalities in symptomatic patients with normal chest radiographs and can be virtually diagnostic in selected entities such as eosinophilic granuloma, lymphangiomyomatosis, or alveolar proteinosis.

Pulmonary Function Testing

Pulmonary function tests provide essential information for diagnosis, staging, prognosis, and longitudinal monitoring. The typical physiologic profile in DILD includes:

• Restrictive ventilatory pattern with reduced lung volumes.
• Normal or increased forced expiratory volume in 1 second/forced vital capacity (FEV₁/FVC) ratio.
• Reduced diffusing capacity for carbon monoxide (DLCO).
• Resting and exertional arterial hypoxemia, with normal or reduced arterial carbon dioxide tension (PaCO₂).

Exercise testing often reveals marked functional limitation driven by oxygen desaturation, altered respiratory mechanics, and, in some cases, coexistent pulmonary vascular disease.

Bronchoscopy, BAL, and Lung Biopsy

When clinical, radiographic, laboratory, and physiologic data are insufficient to determine etiology, bronchoscopy with bronchoalveolar lavage (BAL) and transbronchial lung biopsy is the next diagnostic step. BAL is highly sensitive for certain infections (e.g. Pneumocystis pneumonia in AIDS, with sensitivity around 90–95%) and can diagnose noninfectious entities including alveolar proteinosis, lymphangitic carcinomatosis, alveolar cell carcinoma, and diffuse alveolar hemorrhage.

Cellular analysis of BAL provides useful, though not definitive, clues:

• Neutrophilic alveolitis in IPF, some collagen vascular–related ILD, and asbestosis.
• Lymphocytic alveolitis in sarcoidosis and hypersensitivity pneumonitis, with specific patterns of helper vs suppressor‑cytotoxic T cell predominance distinguishing these conditions.
• Increased eosinophils in chronic eosinophilic pneumonia or acute eosinophilic pneumonia.
• Asbestos bodies in asbestosis, foamy cells in amiodarone toxicity, atypical type II pneumocytes in cytotoxic drug injury, Langerhans cells in eosinophilic granuloma, and hemosiderin‑laden macrophages in alveolar hemorrhage.

Histologic confirmation via lung biopsy—transbronchial, video‑assisted thoracoscopic (VATS), or open surgical—is often required for noninfectious DILD, especially when distinguishing IPF from other idiopathic interstitial pneumonias or excluding malignancy. Transbronchial biopsy is particularly valuable for sarcoidosis (yield 70–90%), infectious infiltrative lung disease, lymphangitic carcinoma, and some drug‑induced or eosinophilic processes; open or VATS biopsy is reserved for diagnostically challenging cases where histologic pattern will significantly influence therapy.

Major Etiologic Categories

Drug‑Induced Diffuse Parenchymal Lung Disease

Drug‑induced DILD, estimated to account for about 3% of infiltrative lung disease, encompasses cytotoxic and non‑cytotoxic agents used in oncology, rheumatology, cardiology, and general practice. Cytotoxic drugs such as bleomycin, cyclophosphamide, methotrexate, nitrosoureas, busulfan, and others can cause interstitial pneumonitis, fibrosis, and diffuse alveolar damage, sometimes with onset weeks or months after exposure has ceased.

Non‑cytotoxic drugs responsible for DILD include:

• Nitrofurantoin, causing acute pleuropulmonary reactions with eosinophilia and chronic fibrosis resembling IPF.
• Amiodarone, associated with dose‑dependent pulmonary toxicity and distinctive BAL findings of foamy macrophages.
• Gold and penicillamine, implicated in interstitial lung disease, alveolar hemorrhage, and drug‑induced autoimmune syndromes.
• Illicit drugs such as injected methylphenidate or cocaine, which can produce talc granulomatosis, alveolar hemorrhage, or BOOP‑like patterns.

Fundamental management principles include prompt drug withdrawal, aggressive exclusion of infection, and, in severe cases, empirical glucocorticoid therapy; prevention strategies rely on dose limitation, monitoring of DLCO and spirometry in high‑risk regimens, and clinician awareness of pulmonary toxicity profiles.

Pneumoconioses

Pneumoconioses result from chronic inhalation of inorganic particulate matter and include asbestosis, silicosis, coal worker’s pneumoconiosis (CWP), and berylliosis. Disease expression depends on particle characteristics, exposure intensity and duration, host defense capacity, and genetically determined inflammatory responses.

Asbestosis presents decades after exposure with progressive dyspnea, fine end‑inspiratory rales, digital clubbing, basilar interstitial opacities, and decreased DLCO; pleural plaques serve as evidence of prior exposure, and excess asbestos fibers in BAL or biopsy samples help confirm diagnosis. Silicosis is characterized radiographically by upper‑lobe nodular opacities and sometimes “eggshell” calcified hilar nodes, and is complicated by increased risk of tuberculosis and atypical mycobacterial infection. CWP shows small rounded opacities and can progress to massive fibrosis with severe dyspnea; berylliosis produces multisystem granulomatous disease mimicking sarcoidosis, distinguishable by exposure history and beryllium‑specific lymphocyte transformation testing.

Hypersensitivity Pneumonitis

Hypersensitivity pneumonitis (allergic alveolitis) is an interstitial lung disease caused by inhalation of organic antigens, most commonly thermophilic actinomycetes in farmer’s lung, bird proteins in pigeon breeder’s disease and bird fancier’s disease, and contaminants in humidifier‑associated disease. Pathogenesis involves complement activation, neutrophilic alveolitis, macrophage activation, monokine release, granuloma formation, and bronchiolitis obliterans.

Acute hypersensitivity pneumonitis presents with fever, chills, cough, dyspnea, and malaise 4–8 hours after heavy antigen exposure; symptoms typically remit after exposure cessation but may recur with continued exposure. Chronic disease manifests as insidious exertional dyspnea and cough with radiographic reticulonodular infiltrates and HRCT features that may distinguish it from IPF. Diagnosis relies on exposure history, temporal association of symptoms with antigen contact, serologic evidence of sensitization, BAL lymphocytosis dominated by suppressor‑cytotoxic T cells, and compatible histology. Treatment emphasizes strict antigen avoidance, environmental remediation, respiratory protection, and glucocorticoids for severe acute or subacute disease, with recognition that fibrotic stages may be less reversible.

Malignant Diffuse Infiltrative Lung Disease

Malignant DILD includes pulmonary lymphangitic carcinomatosis, diffuse alveolar cell carcinoma, and infiltrative lymphoma or leukemia. Lymphangitic carcinomatosis typically arises from adenocarcinomas of the breast, gastrointestinal tract, or lung, presenting with rapidly progressive dyspnea, cough, Kerley B lines, pleural effusions, hilar adenopathy, and poor survival (often 3–6 months). Alveolar cell carcinoma can produce diffuse air‑space opacification mimicking nonmalignant alveolar‑filling processes; diagnosis is made via BAL and transbronchial biopsy. Lymphomatous or leukemic pulmonary involvement commonly coexists with systemic disease and often requires tissue biopsy to distinguish from infection and non‑neoplastic DILD.

Sarcoidosis

Sarcoidosis is a multisystem granulomatous disease of unknown etiology, defined histologically by non‑caseating granulomas and clinically by frequent intrathoracic involvement (bilateral hilar lymphadenopathy and diffuse parenchymal infiltration). It exhibits marked ethnic and geographic variability, being much more prevalent and severe among African Americans in the United States than in whites, with peak onset between ages 20 and 40.

Pathogenesis centers on Th1 helper T‑cell expansion and activation in the lung, driven by macrophage‑derived IL‑1 and IL‑2, with subsequent monocyte recruitment, granuloma formation, and, in some patients, fibroblast activation and fibrosis. Intrathoracic disease is staged radiographically from 0 (normal) to IV (fibrosis with cystic change), with stage‑specific patterns of prognosis and spontaneous remission. Extrapulmonary manifestations include erythema nodosum, granulomatous skin disease (lupus pernio), ocular involvement (uveitis, Heerfordt syndrome), neurologic disease, cardiac arrhythmias and heart block, bone lesions, hepatic and splenic granulomas, upper respiratory tract involvement, and endocrine manifestations such as hypercalcemia and hypercalciuria.

Diagnosis requires tissue demonstration of non‑caseating granulomas and exclusion of mimics such as berylliosis and histoplasmosis, with transbronchial lung biopsy and mediastinoscopy being the primary intrathoracic diagnostic tools. Natural history varies: 60–70% of cases undergo spontaneous remission, 10–30% follow a progressive course, and 1–5% are fatal, with adverse prognostic indicators including lupus pernio, chronic uveitis, older age at onset, hypercalcemia, black race, nasal mucosal involvement, and cystic bone disease.

Idiopathic Interstitial Pneumonias

Idiopathic pulmonary fibrosis (IPF), also known as cryptogenic fibrosing alveolitis, is a prototypical idiopathic interstitial pneumonia characterized by the histologic pattern of usual interstitial pneumonia (UIP), representing patchy subpleural and basal fibrotic remodeling with fibroblastic foci and minimal inflammation. Pathogenesis is thought to involve repetitive epithelial injury, aberrant wound healing, fibroblast and myofibroblast proliferation, excessive matrix deposition, angiogenesis, and defective epithelial repair leading to irreversible fibrosis.

Clinically, IPF affects predominantly older men, presenting with slowly progressive exertional dyspnea, dry end‑inspiratory crackles, and digital clubbing; HRCT typically shows basal and subpleural reticular abnormalities, traction bronchiectasis, and honeycombing. Prognosis is poor, with median survival around 2–3 years and limited response to glucocorticoids or traditional cytotoxic agents.

Other idiopathic interstitial pneumonias include:

• Desquamative interstitial pneumonia/respiratory bronchiolitis–ILD (DIP/RBILD), strongly linked to smoking, characterized histologically by alveolar macrophage accumulation and less severe restriction and better prognosis than IPF.
• Acute interstitial pneumonia (AIP, Hamman‑Rich syndrome), an ARDS‑like presentation with diffuse alveolar damage, high early mortality (33–78%), and potential progression to chronic ILD among survivors.
• Lymphocytic interstitial pneumonia (LIP), often associated with autoimmune disease, dysproteinemias, immunodeficiency, or drugs, showing diffuse B‑cell–predominant lymphocytic infiltration and thin‑walled cysts.
• Nonspecific interstitial pneumonia/fibrosis (NSIP/F), with temporally uniform interstitial inflammation and fibrosis, better steroid responsiveness and survival than IPF, and frequent association with collagen vascular disease and HIV infection.
• Bronchiolitis obliterans organizing pneumonia (BOOP, cryptogenic organizing pneumonia), characterized by intraluminal connective tissue plugs in small airways and alveolar ducts, acute or subacute systemic symptoms, patchy consolidation on imaging, and generally good steroid responsiveness, albeit with relapses.

Eosinophilic Lung Diseases and Alveolar Hemorrhage Syndromes

Chronic eosinophilic pneumonia (CEP) typically affects middle‑aged women with productive cough, dyspnea, fever, wheezing, peripheral blood eosinophilia, and characteristic upper‑lobe peripheral consolidations on imaging. Acute eosinophilic pneumonia presents with abrupt respiratory failure, prominent BAL eosinophilia despite absent blood eosinophilia, and rapid steroid responsiveness with rare relapse.

Alveolar hemorrhage syndromes encompass anti‑glomerular basement membrane (Goodpasture) disease, ANCA‑associated vasculitis, collagen vascular diseases such as SLE, antiphospholipid antibody syndrome, drug‑induced capillaritis, and idiopathic pulmonary hemosiderosis, all presenting with diffuse parenchymal bleeding and often glomerulonephritis. Diagnostic approach includes serologic testing, BAL with iron staining for hemosiderin‑laden macrophages, and biopsy of lung or kidney as appropriate.

Lymphangiomyomatosis and Other Rare Entities

Lymphangiomyomatosis (LAM) is a rare disorder affecting women of childbearing age, presenting with dyspnea, hemoptysis, pneumothorax, and chylothorax, and characterized by obstructive physiology, decreased DLCO, and HRCT showing diffuse thin‑walled parenchymal cysts often accompanied by renal angiomyolipomas and other lymphatic abnormalities. Histology reveals smooth muscle proliferation along lymphatic, vascular, and bronchial structures and in alveolar walls and visceral pleura. LAM frequently overlaps with tuberous sclerosis via TSC2 gene mutations; management includes hormonal manipulation and, in advanced disease, lung transplantation.

Other rare DILD entities include pulmonary alveolar microlithiasis, defined by diffuse calcified microliths in alveolar spaces, occasionally progressive to respiratory failure and managed with bisphosphonates or transplantation, and assorted storage and infiltrative disorders such as Gaucher and Niemann‑Pick diseases.

General Management Principles

Therapeutic strategies for DILD depend on the specific diagnosis, disease severity, and presence of reversible inflammatory activity versus established fibrosis. Evidence‑based data remain limited, with most recommendations derived from non‑randomized case series, clinical experience, and small uncontrolled studies.

Key general principles include:

• Early removal of offending exposures (drugs, occupational dusts, organic antigens), which can yield significant recovery in drug‑induced disease, hypersensitivity pneumonitis, and pneumoconioses.
• Immunization against pneumococcal infection (every 5 years) and annual influenza vaccination, especially in patients with chronic interstitial lung disease.
• Evaluation and treatment of gastroesophageal reflux, notably in IPF and scleroderma‑associated ILD, as a potential contributor to ongoing microaspiration and lung injury.
• Use of bronchodilators in patients with coexistent reversible airflow obstruction, supplemental oxygen at rest and during exertion to improve functional capacity, and standard management of pulmonary hypertension and cor pulmonale in advanced disease.
• Consideration of systemic glucocorticoids and other immunosuppressants in steroid‑responsive conditions such as sarcoidosis, NSIP/F, CEP, BOOP, hypersensitivity pneumonitis, and many autoimmune or vasculitic DILDs, with individualized risk–benefit assessment.
• Early referral for lung transplantation in patients with end‑stage disease, including IPF, LAM, and select other progressive entities, recognizing the potential for post‑transplant disease recurrence in systemic disorders.